This technology is a method of removing disease-associated amyloid fibril deposits using targeted antibodies to enhance the patient’s cellular immune response.
Unmet Need: Effective method for removal or reversal of amyloid fibril deposition
The pathological accumulation of amyloid proteins is implicated in a variety of chronic inflammatory disorders, cancers, and neurodegenerative diseases. However, current approaches for treatment and removal of amyloid deposits, such as high-dose chemotherapy, steroids, and stem cell replacement, are highly invasive but rarely achieve complete remission.
The Technology: Antibody therapy leverages patient’s immune response for amyloid removal
This treatment uses amyloid-directed antibodies to enhance the patient’s own cellular immune clearance mechanism to facilitate removal of disease-associated fibril deposits. The binding of the antibody to the amyloid fibrils, which normally avoid detection by the immune system, triggers a response from the patient’s immune system, facilitating destruction and removal of the deposit.
This technology has been validated in vivo in a mouse model of amyloidosis and is being investigated in human patients.
Applications:
- Treatment for major systemic amyloidoses (e.g. tuberculosis, rheumatoid arthritis, Crohn’s disease)
- Treatment for major localized amyloidoses (e.g. Alzheimer’s disease, Creutzfeld-Jakob disease)
- Treatment for other amyloidoses
Advantages:
- Leverages the patient’s own immune system
- Highly targeted treatment
- Can be used to treat a variety of different types of amyloidoses
Lead Inventor:
Suzanne Lentzsch, M.D., Ph.D.
Patent Information:
Patent Issued (US 8,105,594)
Related Publications:
Edwards CV, Gould J, Langer AL, Mapara M, Radhakrishnan J, Maurer MS, Raza S, Mears JG, Wall J, Solomon A, Lentzsch S. “Interim analysis of the phase 1a/b study of chimeric fibril-reactive monoclonal antibody 11-1F4 in patients with AL amyloidosis” Amyloid. 2017 Mar 16; 24: 58-9.
Langer AL, Miao S, Mapara M, Radhakrishnan J, Maurer MS, Raza S, Mears JG, Solomon A, Lentzsch S. “Results of phase I study of chimeric fibril-reactive monoclonal antibody 11-1F4 in patients with AL amyloidosis” Blood. 2015; 188
Tech Ventures Reference:
